Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers
A Phase 1 Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AD-NP1, a Humanized Monoclonal Antibody Targeting Human ENPP1
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095
- UCLA Clinical and Translational Research Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Body weight ≤ 90kg
- Ability to understand and the willingness to sign a written informed consent document
- Study subject must have read, understood, and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained
- Be in general good health without history of any of the conditions listed in exclusion criteria
- No use of any tobacco products for at least 6 months
- Woman/women of childbearing potential (WOCBP) must agree not to become pregnant from the time of study enrollment until at least 6 months after the completion of the monoclonal antibody infusion. If a WOCBP is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel
- Sexually active male subjects must use a barrier method of contraception during the study
Screening laboratory values must meet the following criteria:
- WBC (>3,000 - <11,000/mm^3)
- Platelets (>100,000/mm^3)
- Hemoglobin (>10.5 gm/dl)
- Creatinine (<1.1 x upper limit of normal [ULN])
- BUN (<1.25 x ULN)
- AST (<1.1 x ULN)
- ALT (<1.1 x ULN)
- Alkaline Phosphatase (<1.1 x ULN)
- Bilirubin (<1.1 x ULN)
- Glucose-non-fasting (> 60 mg/dl and < 115 mg/dl)
- Human immunodeficiency virus (HIV)-infected individuals on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For subjects with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
- Previous exposure to humanized or human monoclonal antibodies whether FDA approved or investigational
- Weight > 90 kg
- History of any of the following illnesses or conditions:
- a. Respiratory condition (such as asthma requiring daily medication)
- b. Clinically immunocompromised due to any primary immune or autoimmune deficiency, as a result of chronic disease, cancer or medication used to treat these diseases
- c. Blood dyscrasias
- d. Psychiatric disorder that precludes compliance with the clinical protocol
- e. Hepatitis
- Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products
- History of drug or alcohol abuse within previous 12 months or a positive urine toxicology screen within 24 hours of initial screening
- History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis
- Physical finding on examination considered clinically significant such as heart murmur (other than functional), hepatosplenomegaly, lymphadenopathy, or focal neurological deficit
- Urinalysis positive for > trace protein, >5 RBC/HPF or >5 WBC/HPF
- Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen
- Positive serum pregnancy test during screening or positive urine pregnancy test within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing
- Currently breast-feeding
- Receipt of an FDA approved vaccine or any investigational study agent within previous 30 days
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Cohort 1 - AD-NP1 (30mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 30 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-Komparator: Cohort 1 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 30 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimental: Cohort 2 - AD-NP1 (40 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 40 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-Komparator: Cohort 2 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 40 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimental: Cohort 3 - AD-NP1 (60 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 60 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-Komparator: Cohort 3 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 60 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
|
Experimental: Cohort 4 - AD-NP1 (100 mg/kg)
Subjects receive a single intravenous dose of AD-NP1 at 100 mg/kg
|
AD-NP1 is a humanized monoclonal antibody targeting the catalytic domain of human ENPP1.
It is administered intravenously at escalating doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg).
|
|
Placebo-Komparator: Cohort 4 - Placebo
Subjects receive a single intravenous dose of placebo matched in volume to the 100 mg/kg dose of AD-NP1
|
Placebo is a normal saline solution administered intravenously in volumes matched to the corresponding AD-NP1 doses (30 mg/kg, 40 mg/kg, 60 mg/kg, and 100 mg/kg)
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety and tolerability of escalating doses of a single IV dose of AD-NP1
Zeitfenster: Day of infusion (Day 0) to 28 days post-dose
|
Assessed by the incidence of treatment-related Adverse Events (AEs) using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
|
Day of infusion (Day 0) to 28 days post-dose
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maximum Tolerated Dose of AD-NP1
Zeitfenster: Day of infusion (Day 0) to 28 days post-dose
|
To be determined based on dose limiting toxicities (DLTs) and adverse events
|
Day of infusion (Day 0) to 28 days post-dose
|
|
Maximum Plasma Concentration (Cmax) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (pre-dose) up to Day 60 post-dose
|
Peak plasma concentration obtained directly from the experimental data points, to be measured in Nanograms per milliliter (ng/mL)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Time to Maximum Plasma Concentration (Tmax) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (pre-dose) up to Day 60 post-dose
|
Tmax presents the time at which Cmax is observed, to be measured in hours (h) and minutes (m)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Area Under the Plasma Concentration-Time Curve (AUC) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
AUC calculated using the linear-log trapezoidal rule from time zero (pre-dose) to the last quantifiable concentration point to be measured in Nanogram x hours per milliliter (ng * h/mL)
|
Baseline (Pre-dose), 30 minutes, 1, 2, 4, 6 hours, and Days 1, 3, 7, 14, 28, 60 post-dose.
|
|
Terminal Elimination Half-life (T(1/2)) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which Ad-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Total Body Clearance (CL) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (pre-dose) up to Day 60 post-dose
|
The rate at which AD-NP1 is cleared from the systemic plasma circulation, to be measured in Liters per hour (L/h) or Milliliters per minute per kilogram (mL/min/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
|
Plasma Uridine Concentration
Zeitfenster: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of uridine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Cytidine Concentration
Zeitfenster: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of cytidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Orotidine Concentration
Zeitfenster: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of orotidine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Adenine Concentration
Zeitfenster: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of adenine will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS)
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Plasma Carbamoyl Aspartate Concentration
Zeitfenster: Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
Plasma concentrations of carbamoyl aspartate will be quantified using Liquid Chromatography-Mass Spectrometry (LC/MS).
|
Baseline (pre-dose), and Days 1, 3, 7, 14, and 28 post-dose.
|
|
Immunogenicity of a single IV dose of AD-NP1
Zeitfenster: Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
Determined by measuring levels of circulating anti-drug antibody in blood samples
|
Baseline (pre-dose) and Days 1, 7, 14, 28, 90, and 180 post-dose
|
|
Apparent Volume of Distribution (Vd) as a pharmacokinetics (PK) parameter
Zeitfenster: Baseline (pre-dose) up to Day 60 post-dose
|
Volume of distribution calculated during the terminal elimination phase following administration, to be measured in Liters (L) or Liters per kilogram (L/kg)
|
Baseline (pre-dose) up to Day 60 post-dose
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 25-1584
- PR250528 (Andere Zuschuss-/Finanzierungsnummer: DOD-DEPARTMENT OF DEFENSE)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .